Home > Insider Trading > Filing (0001209191-18-051836)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1510487	Principia Biopharma Inc.	PRNB	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue, 54Th Floor New York NY 10022		No	No	Yes	No
1502240	Orbimed Capital Gp Iv Llc	601 Lexington Avenue, 54Th Floor New York NY 10022		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-09-18	1,070,771	$0.00	1,070,771	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-09-18	312,741	$0.00	1,383,512	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-09-18	260,617	$0.00	1,644,129	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-09-18	544,047	$0.00	2,188,176	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-09-18	167,537	$0.00	2,355,713	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2018-09-18	250,000	$17.00	2,605,713	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2018-09-18	1,070,771	$0.00	1,070,771	$0.00
Common Stock	Series B-1 Convertible Preferred Stock	Disposition	2018-09-18	312,741	$0.00	312,741	$0.00
Common Stock	Series B-2 Convertible Preferred Stock	Disposition	2018-09-18	260,617	$0.00	260,617	$0.00
Common Stock	Series B-3 Convertible Preferred Stock	Disposition	2018-09-18	544,047	$0.00	544,047	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2018-09-18	167,537	$0.00	167,537	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Warrant (Right to Buy)	$0.00		2022-12-29	28,623	28,623	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2022-12-29	28,623	28,623	Indirect

Footnotes

All series of convertible preferred stock automatically converted into the number of shares of the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.
These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the sole general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors") is the managing member of GP IV. By virtue of such relationships, GP IV and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI IV and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein.
This report on Form 4 is jointly filed by GP IV and Advisors. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
This warrant has converted from a warrant to purchase Series B-3 Preferred Stock into a warrant to purchase Common Stock.
This warrant is exercisable at any time.